Arcellx Says Trial of Multiple Myeloma Drug Candidate Achieves 97% Overall Response Rate

MT Newswires Live2024-12-09

Arcellx (ACLX) said Sunday preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.

Results from the trial at median follow-up of 9.5 months also showed a complete response/stringent complete response rate of 62% with no delayed neurotoxicities, the company said.

Meanwhile, the median progression-free survival and overall survival were not reached, Arcellx said, adding that three deaths "occurred due to treatment-emergent adverse events."

Multiple myeloma is a type of hematological cancer that can cause bone lesions, loss of bone density and bone fractures, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490746834?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-09 17:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490746834","market":"fut","top_or_hot":-1,"title":"Arcellx Says Trial of Multiple Myeloma Drug Candidate Achieves 97% Overall Response Rate","media":"MT Newswires Live","content":"<html><body><p> Arcellx (ACLX) said Sunday preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.</p><p>Results from the trial at median follow-up of 9.5 months also showed a complete response/stringent complete response rate of 62% with no delayed neurotoxicities, the company said.</p><p>Meanwhile, the median progression-free survival and overall survival were not reached, Arcellx said, adding that three deaths \"occurred due to treatment-emergent adverse events.\"</p><p>Multiple myeloma is a type of hematological cancer that can cause bone lesions, loss of bone density and bone fractures, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcellx Says Trial of Multiple Myeloma Drug Candidate Achieves 97% Overall Response Rate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcellx Says Trial of Multiple Myeloma Drug Candidate Achieves 97% Overall Response Rate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 17:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arcellx (ACLX) said Sunday preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.Results ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490746834","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490746834","pubTimestamp":1733735853,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arcellx  said Sunday preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.Results from the trial at median follow-up of 9.5 months also showed a complete response/stringent complete response rate of 62% with no delayed neurotoxicities, the company said.Meanwhile, the median progression-free survival and overall survival were not reached, Arcellx said, adding that three deaths \"occurred due to treatment-emergent adverse events.\"Multiple myeloma is a type of hematological cancer that can cause bone lesions, loss of bone density and bone fractures, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Arcellx表示多发性骨髓瘤候选药物试验总体缓解率达到97%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACLX":0.9},"content_text":"Arcellx (ACLX) said Sunday preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.Results from the trial at median follow-up of 9.5 months also showed a complete response/stringent complete response rate of 62% with no delayed neurotoxicities, the company said.Meanwhile, the median progression-free survival and overall survival were not reached, Arcellx said, adding that three deaths \"occurred due to treatment-emergent adverse events.\"Multiple myeloma is a type of hematological cancer that can cause bone lesions, loss of bone density and bone fractures, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490746834"}